691
Participants
Start Date
July 31, 2009
Primary Completion Date
September 30, 2010
Study Completion Date
April 30, 2011
exenatide once weekly
2.0mg subcutaneous injection, once a week
exenatide twice daily
5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
Research Site, Beijing
Research Site, Chengdu
Research Site, Chongqin
Research Site, Guangzhou
Research Site, Shanghai
Research Site, Ahmedabad
Research Site, Aligarh
Research Site, Bangalore
Research Site, Ghaziabad
Research Site, Hyderabaad
Research Site, Indore
Research Site, Kolkata
Research Site, Mumbai
Research Site, Pune
Research Site, Trivandrum
Research Site, Uttar Pradesh
Research Site, Varanasi
Research Site, Ageo
Research Site, Chiyoda-ku
Research Site, Izumisano
Research Site, Kashiwara
Research Site, Kitaazumi-gun
Research Site, Kumamoto
Research Site, Kurume
Research Site, Matsumoto
Research Site, Matsuyama
Research Site, Miyazaki
Research Site, Osaka
Research Site, Ōita
Research Site, Ōta-ku
Research Site, Shinjuku-ku
Research Site, Takatsuki
Research Site, Yokohama
Research Site, Bucheon-si
Research Site, Daegu
Research Site, Seoul
Research Site, Changhua
Research Site, Chiayi City
Research Site, Kaohsiung City
Research Site, Tainan City
Research Site, Taipei
Research Site, Taoyuan District
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY